Second-line avelumab treatment of patients with metastatic MCC: Experience from a global expanded access program (EAP)

Second-line avelumab treatment of patients with metastatic MCC: Experience from a global expanded access program (EAP);John Walker et al.
A poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting presented data on second-line avelumab treatment of patients with metastatic MCC.  The avelumab EAP rapidly enrolled many pts with metastatic MCC and answered an unmet, urgent medical need for patients ineligible for clinical trials or for whom no approved alternative treatments were available. In a real-world setting, avelumab demonstrated safety and efficacy consistent with the Javelin Merkel 200 registrational study. To view the poster, please click here (Attachment no. 4).